1. Home
  2. FLGT vs REPL Comparison

FLGT vs REPL Comparison

Compare FLGT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fulgent Genetics Inc.

FLGT

Fulgent Genetics Inc.

HOLD

Current Price

$28.05

Market Cap

867.4M

Sector

Health Care

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$7.83

Market Cap

781.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLGT
REPL
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
867.4M
781.3M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
FLGT
REPL
Price
$28.05
$7.83
Analyst Decision
Buy
Buy
Analyst Count
3
9
Target Price
$28.33
$12.00
AVG Volume (30 Days)
205.0K
1.2M
Earning Date
02-27-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$315,549,000.00
N/A
Revenue This Year
$16.84
N/A
Revenue Next Year
$9.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
13.61
N/A
52 Week Low
$14.57
$2.68
52 Week High
$31.04
$14.80

Technical Indicators

Market Signals
Indicator
FLGT
REPL
Relative Strength Index (RSI) 55.75 31.89
Support Level $27.56 $7.87
Resistance Level $28.44 $9.41
Average True Range (ATR) 0.71 0.49
MACD 0.18 -0.20
Stochastic Oscillator 82.51 0.00

Price Performance

Historical Comparison
FLGT
REPL

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: